Clinical Trials Logo

Filter by:
NCT ID: NCT03152565 Completed - Clinical trials for Colorectal Carcinoma

Avelumab Plus Autologous Dendritic Cell Vaccine in Pre-treated Metastatic Colorectal Cancer Patients

AVEVAC
Start date: March 12, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

Single arm Phase I/II multicentric open labeled, with translational sub-study, of avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients..

NCT ID: NCT03152240 Completed - Clinical trials for Myocardial Infarction

Coronary Anatomy Study and Times Since the Onset of Acute Myocardial Infarction Symptoms in Women Until the Opening of the Artery (TAPAC Study)

TAPAC
Start date: November 1, 2017
Phase:
Study type: Observational [Patient Registry]

TAPAC study is an an investigator-driven, observational, prospective,cohort aimed at evaluating differences between men and women in patients undergoing primary angioplasty : hospital medical care, successful markers myocardial reperfusion and the anatomical substrate by describing the underlying coronary anatomy will be compared.

NCT ID: NCT03151551 Completed - Psoriatic Arthritis Clinical Trials

A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis

SPIRIT-H2H
Start date: August 24, 2017
Phase: Phase 4
Study type: Interventional

The main purpose of this study is to evaluate the effectiveness and safety of ixekizumab versus adalimumab in participants with psoriatic arthritis (PsA) who are biologic disease-modifying anti-rheumatic drugs (DMARD) naive.

NCT ID: NCT03150810 Completed - Clinical trials for Locally Advanced or Metastatic Solid Tumors

Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors

Start date: June 28, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The primary objective of this study is to determine the safety and tolerability of pamiparib, the maximum tolerated dose (MTD) or maximum administered dose (MAD) for pamiparib combined with TMZ, to select the recommended Phase 2 dose (RP2D) and schedule of pamiparib in combination with TMZ, and to determine the antitumor activity of pamiparib in combination with TMZ.

NCT ID: NCT03150459 Completed - Cirrhoses, Liver Clinical Trials

Simvastatin Plus Rifaximin in Decompensated Cirrhosis

LIVERHOPE
Start date: July 26, 2017
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to investigate whether the combination of two different drugs, simvastatin and rifaximin, is safe in the treatment of patients with decompensated cirrhosis. The secondary purpose is to see if this combination results in an improvement in inflammation markers in patients with cirrhosis and in an improvement in analytic parameters of progression of liver disease.

NCT ID: NCT03149614 Completed - Neck Pain Clinical Trials

Clinical Effects in Cervical Spinal Mobilization and Oscillation Mobilization in Neck Pain

Start date: May 10, 2017
Phase: N/A
Study type: Interventional

The aim of this study is to compare the clinical effects of spinal mobilization versus vertebral resonant oscillation (POLD) in patients with bilateral mechanical neck pain on pain sensitivity and neck pain intensity.

NCT ID: NCT03148795 Completed - Prostate Cancer Clinical Trials

A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer

Start date: July 4, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this international, phase 2, open-label, response rate study of talazoparib is to assess the efficacy and safety of talazoparib in men with DNA repair defects metastatic castration-resistant prostate cancer (CRPC) who previously received taxane-based chemotherapy and progressed on at least 1 novel hormonal agent (enzalutamide and/or abiraterone acetate/prednisone).

NCT ID: NCT03148769 Completed - Bacteremia Clinical Trials

Spanish Bacteriemia Cohort 2016: Epidemiology, Clinical Management and Prognosis Factors

PRO-BAC
Start date: October 2016
Phase:
Study type: Observational

Bacteremia The Hypothesis of the study are the followings: - To demonstrate relevant epidemiologic and clinical changes with potentially impact in the management and prognosis of the patients with bacteremia. - Since the diagnosis and management is heterogeneous between centers, we could identify a scenario to improve. - To identify quality indicators in the management of bacteremia. - To demonstrate that some interventions made by Bacteremia Team pose relevant impact in the prognosis of bacteremia.

NCT ID: NCT03147703 Completed - Healthy Women Clinical Trials

Timing of Food Intake Impacts Daily Rhythms of Human Saliva Microbiota

ONTIME-MIC
Start date: June 1, 2015
Phase: N/A
Study type: Interventional

The purpose of this investigation is to test the hypothesis that in humans, eating late may induce changes in saliva microbiota daily rhythms towards a more obesogenic and a less responsiveness to dietary treatments profile. These changes in microbiota may partly explain the weight loss difficulties that characterized late eaters in previous studies. Thus, the aim is to analyze the effect of the timing of food intake in humans' saliva microbiome daily rhythms in a randomized, crossover interventional study, in order to achieve.

NCT ID: NCT03147573 Completed - Hypertension Clinical Trials

Validity of 1BPM for Diagnosis of Hypertension

Start date: June 1, 2017
Phase: N/A
Study type: Interventional

Blood pressure measurement methods and conditions are determinants of hypertension diagnosis. The classical methods such as office blood pressure measurement (OBPM) and home blood pressure monitoring (HBPM) have significant limitations. A recent British guideline recommends systematic 24-hour ambulatory blood pressure monitoring (ABPM). However, these devices are not available at all health centers and they can only be used by one patient per day. The aim this study is to validate a new method, 1-hour blood pressure monitoring (1BPM), to diagnose the hypertension. Participants with suspected hypertension will be recruited from a population of patients seen at three primary health centers in an urban area. According to the sample size estimation, a minimum sample size of 214 participants would be needed for the study. Four diagnostic tests will be performed: OBPM at three visits, HBPM, AMPM and 1BPM. The test order for the 24-hour monitoring, and 1-hour monitoring, will be set randomly. Daytime records of ABPM will be compared to all other monitoring methods using the correlation coefficients and Bland Altman plots. The Kappa index will be used to calculate degree of agreement. The sensitivity and specificity of the methods will also be calculated.